Trials / Completed
CompletedNCT04887324
Real-life Data of Constitutional Von Willebrand Disease in Western France
Real-life Data of Constitutional Von Willebrand Disease in Western France: Treatment Outcomes With the Recombinant Von Willebrand Factor
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 922 (actual)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this observational study HOPSCOTcH-WILL II is to provide an accurate and detailed account of current Von Willebrand Disease (VWD) therapeutic management by collecting real-life data on hemorrhagic treated events in the 5 Western French Hemophilia Treatment Center. The HOPSCOTCH-WILL II study aims to describe therapeutic management of patients with VWD, following the provision of a recombinant drug in France; It will also permit to carry out a budget impact analysis to quantify the economic significance of this new era.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | no intervention | no intervention |
Timeline
- Start date
- 2023-07-07
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2021-05-14
- Last updated
- 2025-03-30
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04887324. Inclusion in this directory is not an endorsement.